tiprankstipranks
Nath Bio-Genes (India) Ltd. (IN:NATHBIOGEN)
:NATHBIOGEN
India Market

Nath Bio-Genes (India) Ltd. (NATHBIOGEN) AI Stock Analysis

3 Followers

Top Page

IN:NATHBIOGEN

Nath Bio-Genes (India) Ltd.

(NATHBIOGEN)

Select Model
Select Model
Select Model
Neutral 63 (OpenAI - 5.2)
Rating:63Neutral
Price Target:
₹136.00
▼(-14.36% Downside)
Action:ReiteratedDate:11/25/25
The overall stock score is influenced by strong financial performance and attractive valuation, offset by bearish technical indicators. The company's solid profitability and financial stability are key strengths, but the current negative market momentum poses a risk.
Positive Factors
Revenue Growth
Sustained revenue growth (25% YoY) indicates expanding adoption of the company’s hybrid and improved seed portfolio across field crops. Durable top-line momentum supports reinvestment in R&D, scaling distribution, and helps smooth returns across seasonal cycles.
Negative Factors
Cash Flow Variability
Variable free cash flow conversion creates liquidity uncertainty across planting seasons. This can constrain timely investment in seed R&D, processing upgrades and working capital for peak sowing periods, making operations sensitive to collection and inventory timing.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained revenue growth (25% YoY) indicates expanding adoption of the company’s hybrid and improved seed portfolio across field crops. Durable top-line momentum supports reinvestment in R&D, scaling distribution, and helps smooth returns across seasonal cycles.
Read all positive factors

Nath Bio-Genes (India) Ltd. (NATHBIOGEN) vs. iShares MSCI India ETF (INDA)

Nath Bio-Genes (India) Ltd. Business Overview & Revenue Model

Company Description
Nath Bio-Genes (India) Limited engages in the production, processing, and marketing of hybrid and GM seeds in India and internationally. It operates in two segments, Agricultural Activities and Trading Activities. The company offers seeds for cere...
How the Company Makes Money
The company primarily makes money by selling crop seeds to the agricultural market. Its core revenue stream is the sale of proprietary and licensed seed products (commonly including hybrid and improved varieties), distributed through agricultural ...

Nath Bio-Genes (India) Ltd. Financial Statement Overview

Summary
Nath Bio-Genes demonstrates strong profitability and financial stability with positive growth trends. The company effectively manages its equity and debt levels but should monitor cash flow variability for sustained liquidity.
Income Statement
72
Positive
Balance Sheet
68
Positive
Cash Flow
65
Positive
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue4.16B3.65B2.48B3.01B2.78B3.07B
Gross Profit2.18B2.29B1.03B1.67B1.54B1.71B
EBITDA629.40M497.98M536.39M488.91M-497.06M684.33M
Net Income462.29M386.00M396.19M350.11M-673.38M556.62M
Balance Sheet
Total Assets10.14B10.26B8.80B7.93B7.42B7.90B
Cash, Cash Equivalents and Short-Term Investments1.59B888.99M774.10M379.90M41.68M292.11M
Total Debt1.55B1.23B1.10B1.05B929.59M965.67M
Total Liabilities3.34B3.82B2.70B2.20B2.00B1.76B
Stockholders Equity6.80B6.44B6.10B5.73B5.42B6.13B
Cash Flow
Free Cash Flow-1.10B96.61M478.18M358.18M-39.70M-104.86M
Operating Cash Flow-1.09B175.81M745.94M383.67M170.46M11.13M
Investing Cash Flow-11.48M-39.62M-274.01M-28.84M-198.66M-102.82M
Financing Cash Flow216.74M-21.30M-77.78M-16.68M-222.27M164.01M

Nath Bio-Genes (India) Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price158.80
Price Trends
50DMA
144.69
Positive
100DMA
149.34
Negative
200DMA
165.14
Negative
Market Momentum
MACD
-0.26
Negative
RSI
59.86
Neutral
STOCH
73.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NATHBIOGEN, the sentiment is Positive. The current price of 158.8 is above the 20-day moving average (MA) of 140.70, above the 50-day MA of 144.69, and below the 200-day MA of 165.14, indicating a neutral trend. The MACD of -0.26 indicates Negative momentum. The RSI at 59.86 is Neutral, neither overbought nor oversold. The STOCH value of 73.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NATHBIOGEN.

Nath Bio-Genes (India) Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
₹3.50B10.144.81%
63
Neutral
₹2.84B46.031.26%18.68%16.47%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
62
Neutral
₹4.77B6.170.38%13.83%33.88%
59
Neutral
₹2.64B33.2113.15%-20.51%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:NATHBIOGEN
Nath Bio-Genes (India) Ltd.
149.20
-1.07
-0.71%
IN:ARIES
Aries Agro Ltd.
366.60
111.40
43.65%
IN:CONTI
Continental Seeds & Chemicals Ltd.
13.00
-15.50
-54.39%
IN:GOODRICKE
Goodricke Group Ltd
162.25
-18.00
-9.99%
IN:HARRMALAYA
Harrisons Malayalam Ltd
189.50
-2.70
-1.40%
IN:NOVAAGRI
Nova Agritech Limited
28.53
-17.00
-37.34%

Nath Bio-Genes (India) Ltd. Corporate Events

Nath Bio-Genes Releases Investor Presentation on Unaudited Q3 and 9MFY26 Results
Jan 31, 2026
Nath Bio-Genes (India) Ltd. has released an investor presentation covering its unaudited financial results for the quarter and nine months ended 31 December 2025, and has submitted this information to both BSE and the National Stock Exchange of In...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 25, 2025